Preparation and characterization of Biochanin A loaded solid lipid nanoparticles
Main Article Content
Abstract
efficiency (EE), and drug loading capacity (DL) of BCA was 176.0 nm, −18.7 ± 0.26, 97.15 ± 0.28%, and 6.38 ± 0.04%, respectively. The results of differential scanning calorimetry (DSC) and Xâ€ray diffraction analysis (XRD) indicated that the BCA was wrapped and absorbed in the nanoparticles. The solution of preparation is much higher than the untreated BCA.Results of stability of SLN showed a relatively shortâ€term stability after storage at 4°C and 25°C for 15 days. Drug release of untreated BCA and BCAâ€SLN was fit into the Biexponential equations and Weibull equations, respectively, and SLN showed sustained release properties. But after freezeâ€dried, stability was improved, and the EE and DL had a slightly decrease. The mean particle size was slightly increased, but the structure was not changed. In conclusion, SLN systems can represent an
effective strategy to change the poor aqueous solubility and prolong the halfâ€time of BCA.
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Chen HQ, Zheng YJ, Li GH. Biochanin A protects dopaminergic neurons
against lipopolysaccharideâ€induced damage through inhibition of
microglia activation and proinflammatory factors generation. Neurosci
Lett 2007;417:112â€7.
LapcÃk O, VÃtková M, Klejdus B, Alâ€Maharik N, Adlercreutz H.
Immunoassay for biochanin A. J Immunol Methods 2004;294:155â€63.
Küçükboyacı N, Güvenç A, Dinç E, Adıgüzel N, Bani B. New
HPLC†chemometric approaches to the analysis of isoflavones in
Trifolium lucanicum Gasp. J Sep Sci 2010;33:2558â€67.
Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A.
Estrogenic activity of two standardized red clover extracts (menoflavon)
intended for large scale use in hormone replacement therapy. J Steroid
Biochem Mol Biol 2001;78:65â€75.
Kole L, Giri B, Manna SK. Biochaninâ€A, an isoflavon, showed
antiâ€proliferative and antiâ€inflammatory activities through the inhibition
of iNOS expression, p38â€MAPK and ATFâ€2 phosphorylation and blocking
NFκB nuclear translocation. Eur J Pharmacol 2011;653:8â€15.
Lee KH, Choi EM. Biochanin A Stimulates Osteoblastic Differentiation
and Inhibits Hydrogen Peroxideâ€Induced Production of Inflammatory
Mediators in MC3T3â€E1 Cells. Biol Pharm Bull 2005;28:1948â€53.
Lin VC, Ding HY, Tsai PC, Wu JY, Lu YH, Chang TS. In vitro and in vivo
Melanogenesis Inhibition by Biochanin A from Trifolium pratense. Biosci
Biotechnol Biochem 2011;75:914â€8.
Szliszka E, Czuba ZP, Mertas A, Paradysz A, Krol W. The dietary
isoflavone biochaninâ€A sensitizes prostate cancer cells to TRAILâ€induced
apoptosis. Urol Oncol 2011. [Epub ahead of print]
Hsu JT, Hung HC, Chen CJ, Hsu WL, Ying C. Effects of the dietary
phytoestrogen biochanin A on cell growth in the mammary carcinoma
cell line MCFâ€7. J Nutr Biochem 1999;10:510â€7.
Moon YJ, Shin BS, An G, Morris ME. Biochanin A Inhibits Breast
Cancer Tumor Growth in A Murine Xenograft Model. Pharm Res
;25:2158â€63.
Han EH, Kim JY, Jeong HG. Effect of Biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCFâ€7 human breast carcinomacells. Arch Pharm Res 2006;29:570â€6.
Lee YS, Seo JS, Chung HT, Jang JJ. Inhibitory effects of Biochanin A
on mouse lung tumor induced benzo(a)pyrene. J Korean Med Sci
;6:325â€8.
Mansoor TA, Ramalho RM, Luo X, Ramalhete C, Rodrigues CM,
Ferreira MJ. Isoflavones as Apoptosis Inducers in Human Hepatoma
HuHâ€7 Cells. Phytother Res 2011;25:1819â€24.
Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects
of isoflavones on human cancer cell lines established from the
gastrointestinal tract. Cancer Res 1993;53:5815â€21.
Fung MC, Szeto YY, Leung KN, Wongâ€Leung YL, Mak NK. Effects of
biochanin A on the growth and differentiation of myeloid leukemia
wehiâ€3B (JCS) cells. Life Sci 1997;61:105â€15.
Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin,
phloretin, and silymarin on Pâ€glycoproteinâ€mediated transport.
J Pharmacol Exp Ther 2003;304:1258â€67.
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I,
Gottesman MM. Biochemical, cellular, and pharmacological aspects of
the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361â€98.
Han HK, Lee HK. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: In vitro and in vivo evaluation. Int J Pharm 2011;415:89â€94.
Moon YJ, Sagawa K, Frederick K, Zhang S, Morris ME. Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. The AAPS Journal 2006;8:E433â€42.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for
controlled drug deliveryâ€a review of the state of the art. Eur J Pharm
Biopharm 2000;50:161â€77.
Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K.
Investigations on the structure of solid lipid nanoparticles (SLN) and
oilâ€loaded solid lipid nanoparticles by photon correlation spectroscopy,
fieldâ€flow fractionation and transmission electron microscopy. J Control
Release 2004;95:217â€27.
Bummer PM. Physical chemical considerations of lipidâ€based oral drug
delivery - solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst
;21:1â€20.
Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles
as drug delivery systems. Methods Find Exp Clin Pharmacol
;27:127â€44.
Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid
nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci
;42:11â€8.
Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability
enhancer vehicle. Expert Opin Drug Deliv 2011;8:1407â€24.
Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral
bioavailability of Cryptotanshinoneâ€loaded Solid lipid nanoparticles.
AAPA PharmSci Tech 2010;11:582â€7.
Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles
and nanosuspension of adefovir dipivoxil for bioavailability
improvement: Formulation, characterization, pharmacokinetic and
biodistribution studies. Drug Dev Ind Pharm 2012 Jun 12 [Epub ahead
of print].Dai W, Zhang D, Duan C, Jia L, Wang Y, Feng F, et al. Preparation and characteristics of oridoninâ€loaded nanostructured lipid carriers as a
controlledâ€release delivery system. J Microencapsul 2010;27:234â€41.
Yang CR, Zhao XL, Hu HY, Li KX, Sun X, Li L, et al. Preparation,
optimization and characteristic of huperzine A loaded nanostrured
lipid carriers. Chem Pharm Bull 2010;58:656â€61.
Attama AA, Schicke BC, Paepenmüller T, Müllerâ€Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid:
Characterization. Eur J Pharm Biopharm 2007;67:48â€57.
Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627â€38.
Kuo YC, Chung JF. Physicochemical properties of nevirapineâ€loaded
solid lipid nanoparticles and nanostructured lipid carriers. Colloids
Surf B Biointerfaces 2011;83:299â€306.
Bayindir ZS, Yuksel N. Characterization of niosomes prepared with
various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci
;99:2049â€60.
Lin XH, Li XW, Zheng LQ, Yu L, Zhang QQ, Liu WC. Preparation and
characterization of monocaprate nanostructured lipid carriers. Colloids
Surf A Physicochem Eng Aspects 2007;311:106â€11.
Han F, Li SM, Yin R, Liu HZ, Xu L. Effect of surfactants on the formation
and characterization of a new type of colloidal drug delivery system:
Nanostructured lipid carriers. Colloids Surf A: Physicochem Eng Aspects
;315:210â€6.
Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid
lipid nanoparticle carrier system based on binary mixtures of liquid
and solid lipids. Int J Pharm 2000;199:167â€77.